Compass Capital Management Inc. Has $44.61 Million Holdings in Boston Scientific Corporation $BSX

Compass Capital Management Inc. grew its position in shares of Boston Scientific Corporation (NYSE:BSX) by 21.7% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 710,874 shares of the medical equipment provider’s stock after purchasing an additional 126,806 shares during the quarter. Boston Scientific comprises approximately 2.6% of Compass Capital Management Inc.’s investment portfolio, making the stock its 24th largest position. Compass Capital Management Inc.’s holdings in Boston Scientific were worth $44,607,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the company. Norges Bank acquired a new stake in shares of Boston Scientific during the fourth quarter worth $2,199,395,000. Assenagon Asset Management S.A. lifted its holdings in Boston Scientific by 133.6% in the first quarter. Assenagon Asset Management S.A. now owns 10,057,936 shares of the medical equipment provider’s stock valued at $631,135,000 after buying an additional 5,751,760 shares during the period. Janus Henderson Group PLC boosted its position in Boston Scientific by 31.0% during the first quarter. Janus Henderson Group PLC now owns 16,497,366 shares of the medical equipment provider’s stock valued at $1,035,202,000 after acquiring an additional 3,907,981 shares during the last quarter. Maverick Capital Ltd. bought a new stake in Boston Scientific during the fourth quarter valued at $280,735,000. Finally, Arrowstreet Capital Limited Partnership grew its holdings in Boston Scientific by 25.9% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 13,891,668 shares of the medical equipment provider’s stock worth $871,702,000 after acquiring an additional 2,856,040 shares during the period. Institutional investors and hedge funds own 89.07% of the company’s stock.

More Boston Scientific News

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Boston Scientific reported second-quarter adjusted earnings of $0.86 per share and revenue of $5.44 billion, exceeding consensus estimates of $0.83 and $5.38 billion, respectively. Revenue increased 7.5% year over year, while management highlighted approximately 7% organic sales growth and a 15% increase in adjusted EPS. Boston Scientific Q2 earnings call highlights
• Positive Sentiment: Management’s multiyear restructuring plan is intended to improve efficiency and generate roughly $500 million in savings, supporting longer-term margins despite restructuring costs of up to $800 million. Reported workforce reductions are expected to affect operations in Ireland and Costa Rica. Boston Scientific restructuring cuts
• Positive Sentiment: Penumbra reported second-quarter revenue of $390.0 million, up 14.9% year over year, with thrombectomy revenue rising 12.5% and embolization and access revenue increasing 20.0%. The results provide supportive operating momentum for Boston Scientific’s pending acquisition of Penumbra, although PEN will not issue full-year guidance during the transaction. Penumbra second-quarter financial results
• Neutral Sentiment: Analyst sentiment remains broadly constructive but more cautious: UBS reaffirmed a Buy rating with a $74 target, while TD Cowen and Truist maintained Buy ratings despite lowering targets to $56 and $57. Argus reiterated a Hold rating, and BTIG reduced its expectations.
• Negative Sentiment: Boston Scientific lowered its full-year outlook because of headwinds affecting its electrophysiology and WATCHMAN portfolios. Analysts also cited a reset in expectations for these businesses, limiting the near-term upside from the earnings beat. Boston Scientific lowered full-year guidance
• Negative Sentiment: A recall involving the Rapid Refill Continuous Injection System adds a product and execution risk, while the restructuring will create near-term charges before expected savings are realized. Boston Scientific earnings, recall and restructuring

Insider Buying and Selling

In other news, Director Cheryl Pegus purchased 1,770 shares of the company’s stock in a transaction that occurred on Wednesday, May 20th. The shares were acquired at an average cost of $56.49 per share, with a total value of $99,987.30. Following the purchase, the director owned 1,770 shares in the company, valued at $99,987.30. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Edward J. Ludwig purchased 3,580 shares of the business’s stock in a transaction on Wednesday, May 20th. The stock was purchased at an average price of $56.68 per share, for a total transaction of $202,914.40. Following the acquisition, the director owned 25,359 shares of the company’s stock, valued at approximately $1,437,348.12. This represents a 16.44% increase in their position. The disclosure for this purchase is available in the SEC filing. In the last three months, insiders have bought 9,800 shares of company stock valued at $554,012. 0.34% of the stock is owned by company insiders.

Boston Scientific Trading Up 1.6%

BSX opened at $46.75 on Friday. The company has a fifty day moving average price of $46.13 and a two-hundred day moving average price of $62.26. Boston Scientific Corporation has a 1-year low of $42.20 and a 1-year high of $109.50. The company has a market cap of $69.48 billion, a P/E ratio of 18.93, a price-to-earnings-growth ratio of 0.94 and a beta of 0.58. The company has a current ratio of 1.90, a quick ratio of 1.22 and a debt-to-equity ratio of 0.42.

Boston Scientific (NYSE:BSX) last released its quarterly earnings data on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.83 by $0.03. The company had revenue of $5.44 billion for the quarter, compared to analysts’ expectations of $5.38 billion. Boston Scientific had a net margin of 17.50% and a return on equity of 19.36%. The business’s revenue was up 7.5% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.75 EPS. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. Analysts predict that Boston Scientific Corporation will post 3.3 EPS for the current fiscal year.

Boston Scientific announced that its board has initiated a stock repurchase plan on Monday, May 18th that allows the company to repurchase $5.00 billion in shares. This repurchase authorization allows the medical equipment provider to reacquire up to 6.4% of its shares through open market purchases. Shares repurchase plans are often an indication that the company’s management believes its stock is undervalued.

Analysts Set New Price Targets

Several research firms have recently weighed in on BSX. UBS Group lowered their price objective on Boston Scientific from $74.00 to $67.00 and set a “buy” rating for the company in a research report on Thursday. Canaccord Genuity Group cut their target price on Boston Scientific from $70.00 to $66.00 and set a “buy” rating on the stock in a research report on Thursday. Weiss Ratings cut Boston Scientific from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Tuesday, July 7th. Stifel Nicolaus set a $60.00 target price on Boston Scientific in a report on Wednesday. Finally, Oppenheimer dropped their price target on Boston Scientific from $90.00 to $85.00 and set an “outperform” rating on the stock in a research note on Monday, July 27th. Twenty-four analysts have rated the stock with a Buy rating, five have given a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $71.62.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.